BioSpace News Archive

Civica Inc. is proud to announce that pharmaceutical industry leader Bouwien Smits has joined Civica as the new Site Vice President and General Manager of the company’s new sterile injectable manufacturing facility.

Ligand Pharmaceuticals Incorporated announced that it has acquired Tolerance Therapeutics, Inc. for $20 million in cash.

Ashvattha Therapeutics today announced that the first patient has been dosed with D-4517.2, a subcutaneously administered anti-angiogenic therapeutic, in a Phase 2 chronic dosing study. The open-label study will evaluate the safety and efficacy of chronic D-4517.2 dosing in patients with wet AMD and DME.

Kyverna Therapeutics (“Kyverna”), a clinical-stage cell therapy company with the mission of engineering a new class of therapies for serious autoimmune diseases, today announced the signing of a multi-year research funding agreement with Charité - Universitätsmedizin Berlin, Department of Rheumatology and Clinical Immunology to investigate the impact of B- and plasma cell-targeting therapies.

Electromed, Inc. today announced that Jim Cunniff, President and Chief Executive Officer, and Brad Nagel, Chief Financial Officer, are scheduled to attend the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 16, 2023 at the Westin NY Grand Central in New York City.

Napo Pharmaceuticals (Napo), a Jaguar Health (NASDAQ:JAGX) (Jaguar) family company, today announced that the United States Patent and Trademark Office on October 10, 2023 issued a new U.S. patent to Napo for methods for treating short bowel syndrome (SBS), bile acid diarrhea, and diarrhea associated with small intestine resection or gallbladder removal, in patients with an inhibitor of chloride-ion transport such as crofelemer, Napo’s novel plant-based prescription drug.

Evolus, Inc. today announced that members of its management team will present at the following investment conferences in November.

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Sam Raha as Chief Operating Officer (COO), effective December 11, 2023.

Ethris GmbH, a leading biotechnology company pioneering next-generation messenger RNA therapeutics and vaccines, announced it will be a founding member of a new global organization called Alliance for mRNA Medicines.

Soterios Pharma, a privately held clinical-stage pharmaceutical company, announced today that it has completed target enrolment for its Phase II trial with STS-01 for mild / moderate (patchy) alopecia areata.